Soleno Therapeutics (SLNO) · page 66 of 415
This slide is part of a series of 'investigator' profiles used to build a case against a company's clinical trial results.
Activist deck · nominee_bio · introduce_nominees · overcrowded density
Slide locked Sign in to view
Slide schematic 7/9
callout 0/1 list 5/5 quote 0/1 source-note 1/1 title 1/1
2 without position callout 1 · quote 1
calloutquote
Components 9
callout bullet bullet bullet bullet bullet quote source-note headline
Tools 2
Anadiplosis slide · 70%
The investigator indicated that PWS patients are already at risk of elevated pulmonary pressures, thereby exacerbating the risk of cardiac events: “they’re likely to have problems with their left ventricular
Call-and-Response slide · 70%Stated that the trial was functionally unblinded due to hair growth and edema, making it easy to deduce who was on drug; and because Vykat tablets smelled different than placebo, which families figured ou
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.